A Phase 2 interventional study of Celecoxib in Oral Squamous Cell Carcinoma, sponsored by China Medical University Hospital. Status unknown at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-04-15.
Sponsored by China Medical University Hospital · Phase 2, Interventional, and Prevention
The research and development of novel anti-tumor agents in oral cancer is slow, the investigation of repositioning use of currently available drugs in clinical, such as a selective cyclooxygenase-2 (COX-2) inhibitor (Celebrex/Celecoxib) maybe a potential alternative strategy.
Celebrex (Celecoxib) is a form of non-steroidal anti-inflammatory drug that directly targets COX-2 enzyme to block the inflammatory signaling and has been approved to treat colon cancer. In our preliminary findings, Celecoxib significantly inhibited cell growth,proliferation, migration, invasion and epithelial-mesenchymal transition programs in oral squamous cell carcinoma cell (OSCC) lines. The Institutional Review Board in China Medical University Hospital (CMUH) has approved the combination treatment of concurrent radiotherapy (RT) and/or Cisplatin with or without Celecoxib in a phase II clinical trial for relapse-free primary OSCC patients.
6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.
This study's planned enrollment of 270 is above the median of 45 across 5,170 interventional studies indexed under Carcinoma.
Browse Carcinoma studies →China Medical University Hospital is the lead sponsor of 464 studies on the registry; 116 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Combination of concurrent radiotherapy and/or Cisplatin with or without Celcoxib
Drug: Celecoxib
200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months
Also known as: Celebrex
Relapse-free recurrence
3-year follow-up after 6-month treatment of Celecoxib
Time frame: 3 year relapse-free recurrence
Relapse-free survival
3-year follow-up after 6-month treatment of Celecoxib
Time frame: 3 year relapse-free survival
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
China Medical University Hospital